Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase 3 1Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 39NET 27Gastrointestinal 6Thoracic 3CNS 3Head & Neck 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Brain Neoplasms 593Glioblastoma 573Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Recurrence 56Melanoma 56Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

Erlotinib Hydrochloride 2pertuzumab 1Everolimus 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × CNS × Clear all
NCT02441062 2020-12-21

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

University of Iowa

Phase 2 Completed
122 enrolled 6 charts
CNSEndocrineNET

Carcinoid Tumor, Medulloblastoma, Neuroblastoma, Neuroendocrine Tumors

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡